A 50+ Sunscreen Containing Polypodium Leucotomos Extract, Ellagic Acid, and Niacinamide in Facial Melasma and Photoaging‐Related Hyperpigmentation: A Pilot Observational Study Using Line‐Field Confocal Optical Coherence Tomography
Journal of Cosmetic Dermatology · 2026-02 · 25 (2)
DOI: 10.1111/jocd.70732 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Cosmetic Dermatology, online erschienen am 08.02.2026. Verfasst von Alessia Villani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dermatologia Azienda Ospedaliero Universitaria Federico II -Napoli, Naples, Italy. Hauptthemen laut MEDLINE: Sunscreening Agents, Niacinamide, Melanosis, Plant Extracts. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Melasma is an acquired facial hyperpigmentation disorder that disproportionately affects sun‐exposed areas. Current treatments show limited efficacy and tolerability.
Aim
To assess, in a non‐controlled prospective pilot trial, the efficacy of a fluid cream SPF 50+ sunscreen containing ellagic acid, niacinamide, and a non‐UV‐filtering extract of Polypodium leucotomos (PLE).
Methods
Twenty women (mean age 40 ± 10 years) with melasma or sun‐induced hyperpigmentation applied the sunscreen every morning and every 2 h during sun exposure for 12 weeks. The primary endpoint was the change in Melasma Area and Severity Index (MASI) at week 12 and week 24 (follow‐up). The secondary endpoints were Line‐field Confocal Optical Coherence Tomography (LC‐OCT) evaluation of pigment distribution and hyper‐reflective cells. Local tolerability was also assessed.
Results
All subjects completed the study. Baseline MASI (6.9 ± 3.2) decreased to 4.4 ± 3.3 at week 12 and 3.9 ± 3.1 at week 24 (−44% from baseline, p = 0.0001). LC‐OCT pigment scores declined from 2.2 ± 0.8 to 1.5 ± 0.6 at week 24 ( p = 0.04), and hyper‐reflective cells decreased from 47% to 26%. The product was well tolerated, with tolerability scores near to zero.
Conclusion
This pilot proof‐of‐concept study suggests that an SPF 50+ sunscreen containing ellagic acid, niacinamide, and PLE may reduce melasma severity and improve hyperpigmentation with excellent tolerability. These findings warrant confirmation in larger controlled trials. Trial Registration clinical registration number ISRCTN18053239
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dermatologia Azienda Ospedaliero Universitaria Federico II -Napoli, Naples, Italy.
- Cantabria Labs Difa Cooper MD, Caronno Pertusella, Italy.
ORCID-Profile: Luigi Coronella, Massimo Milani, Francesca Colombo
Zitieren
APA
Villani, A., Genco, L., Coronella, L., Ventura, V., Milani, M., Alfano, S., & Colombo, F. (2026). A 50+ Sunscreen Containing Polypodium Leucotomos Extract, Ellagic Acid, and Niacinamide in Facial Melasma and Photoaging‐Related Hyperpigmentation: A Pilot Observational Study Using Line‐Field Confocal Optical Coherence Tomography. Journal of Cosmetic Dermatology, 25(2). https://doi.org/10.1111/jocd.70732
Vancouver
Villani A, Genco L, Coronella L, Ventura V, Milani M, Alfano S, et al. A 50+ Sunscreen Containing Polypodium Leucotomos Extract, Ellagic Acid, and Niacinamide in Facial Melasma and Photoaging‐Related Hyperpigmentation: A Pilot Observational Study Using Line‐Field Confocal Optical Coherence Tomography. Journal of Cosmetic Dermatology. 2026;25(2). doi:10.1111/jocd.70732
BibTeX
@article{Villani2026,
author = {Villani, Alessia and Genco, Lucia and Coronella, Luigi and Ventura, Valentina and Milani, Massimo and Alfano, Stefano and Colombo, Francesca},
title = {A 50+ Sunscreen Containing Polypodium Leucotomos Extract, Ellagic Acid, and Niacinamide in Facial Melasma and Photoaging‐Related Hyperpigmentation: A Pilot Observational Study Using Line‐Field Confocal Optical Coherence Tomography},
journal = {Journal of Cosmetic Dermatology},
year = {2026},
volume = {25},
number = {2},
doi = {10.1111/jocd.70732}
}
EUVIMED